852433-84-2

Basic information

• Product Name: Dovitinib Dilactic acid (TKI258 Dilactic acid)
• Synonyms: Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone;Dovitinib dilactic acid, >=99%;Dovitinib Dilactic acid (TKI258 Dilactic acid);2-Hydroxypropanoic acid compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone;Dovitinib dilactic acid;TKI258 Dilactic acid;Dovitinib (TKI-258) Dilactic Acid
• CAS NO: 852433-84-2
• Molecular Formula: C21H21FN6O.2(C3H6O3)
• Molecular Weight: 572.59
• Product Categories: Inhibitors
• Mol File: 852433-84-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Dovitinib Dilactic acid (TKI258 Dilactic acid)(CAS DataBase Reference)
• NIST Chemistry Reference: Dovitinib Dilactic acid (TKI258 Dilactic acid)(852433-84-2)
• EPA Substance Registry System: Dovitinib Dilactic acid (TKI258 Dilactic acid)(852433-84-2)

Safety Data

• Hazardous Substances Data: 852433-84-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Dovitinib Dilactic acid (TKI258 Dilactic acid) is used as a therapeutic agent for the treatment of various cancers. Its multitargeted inhibition of RTKs, particularly class III and class IV, makes it a promising candidate for addressing cancer cells with aberrant RTK signaling pathways. This can lead to the suppression of tumor growth, angiogenesis, and metastasis, offering a potential treatment option for patients with cancer.
Used in Cancer Research:
In the field of cancer research, Dovitinib Dilactic acid (TKI258 Dilactic acid) serves as a valuable tool for studying the role of RTKs in cancer development and progression. Its ability to target multiple RTKs allows researchers to investigate the complex interactions between these proteins and their downstream signaling pathways, providing insights into the molecular mechanisms underlying cancer and identifying potential therapeutic targets.
Used in Drug Development:
Dovitinib Dilactic acid (TKI258 Dilactic acid) is utilized in drug development as a lead compound for the design and synthesis of novel multitargeted RTK inhibitors. Its multifaceted inhibitory profile offers a foundation for the development of more potent and selective agents, which can be tailored to target specific cancer types or overcome resistance to existing treatments.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of Dovitinib Dilactic acid (TKI258 Dilactic acid), it can be incorporated into various drug delivery systems. These systems, such as nanoparticles, liposomes, or hydrogels, can improve the drug's solubility, stability, and targeted delivery to cancer cells, thereby increasing its therapeutic potential and reducing side effects.

Upstream product

• 405169-16-6 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 
• 849585-22-4 LACTIC ACID 
• 109-01-3 1-methyl-piperazine 
• 402948-37-2 [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]acetic acid ethyl ester 
• 1635-61-6 5-chloro-2-nitroaniline 
• 54998-08-2 4-(4-methylpiperazino)-1,2-diaminobenzene 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 
• 692737-80-7 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one DL-lactic acid salt 

Relevant articles and documents

PREPARATION OF HYDRATED POLYMORPHS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALT

The present technology provides methods of making anhydrous crystalline Form II and monohydrate crystalline Form S of the lactic acid salt of 4-amino-5-fluoro-3-(6-{4-mefhyipiperazin- 1 -yl)-l H-benzimidazol-2-yl)-1H-quinoiin-2-one.

CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE LACTIC ACID SALTS

[0057] Crystalline forms or polymorphs of 4-amino-5-fIuoro-3-[5-(4-methylpiperazin-1- yl)-1H-benzimidazol-2-yl]quinoIin-2(1 H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.

TREATMENT OF MELANOMA

Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp

Formulation of Quinolinones

A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) sil

CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS

The present invention relates to non-hydrate crystalline forms of 4-amino- 5-fluoro-3 -[6-(4-methylpiperazin- 1 -yl)- 1 H-benzimidazol-2-yl] - 1 H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-arnino-5-fiuoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.

METHODS FOR TREATING DRUG RESISTANT CANCER

A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comp

TREATMENT OF METASTASIZED TUMORS

Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mix

METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS

A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reac

MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES

Methods of using compounds having Structure (I) or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.